JP2023508097A5 - - Google Patents

Info

Publication number
JP2023508097A5
JP2023508097A5 JP2022539058A JP2022539058A JP2023508097A5 JP 2023508097 A5 JP2023508097 A5 JP 2023508097A5 JP 2022539058 A JP2022539058 A JP 2022539058A JP 2022539058 A JP2022539058 A JP 2022539058A JP 2023508097 A5 JP2023508097 A5 JP 2023508097A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound according
optical isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022539058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508097A (ja
JP7791087B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/138572 external-priority patent/WO2021129653A1/zh
Publication of JP2023508097A publication Critical patent/JP2023508097A/ja
Publication of JP2023508097A5 publication Critical patent/JP2023508097A5/ja
Application granted granted Critical
Publication of JP7791087B2 publication Critical patent/JP7791087B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022539058A 2019-12-23 2020-12-23 タンパク質分解剤化合物の製造方法及び使用 Active JP7791087B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201911342649 2019-12-23
CN201911342649.0 2019-12-23
CN202010200682 2020-03-20
CN202010200682.6 2020-03-20
CN202010496353.0 2020-06-03
CN202010496353 2020-06-03
CN202011486334.6 2020-12-16
CN202011486334 2020-12-16
PCT/CN2020/138572 WO2021129653A1 (zh) 2019-12-23 2020-12-23 一种蛋白降解剂化合物的制备方法和应用

Publications (3)

Publication Number Publication Date
JP2023508097A JP2023508097A (ja) 2023-02-28
JP2023508097A5 true JP2023508097A5 (enExample) 2024-01-09
JP7791087B2 JP7791087B2 (ja) 2025-12-23

Family

ID=76573691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539058A Active JP7791087B2 (ja) 2019-12-23 2020-12-23 タンパク質分解剤化合物の製造方法及び使用

Country Status (19)

Country Link
US (3) US12441706B2 (enExample)
EP (1) EP4083020A4 (enExample)
JP (1) JP7791087B2 (enExample)
KR (1) KR20220120629A (enExample)
CN (2) CN113087704B (enExample)
AU (1) AU2020414151A1 (enExample)
BR (1) BR112022012385A2 (enExample)
CA (1) CA3162523A1 (enExample)
CL (1) CL2022001724A1 (enExample)
CO (1) CO2022010305A2 (enExample)
EC (1) ECSP22056811A (enExample)
IL (1) IL294225B2 (enExample)
JO (1) JOP20220159A1 (enExample)
MX (1) MX2022007885A (enExample)
PE (1) PE20230114A1 (enExample)
PH (1) PH12022551571A1 (enExample)
TW (1) TWI755992B (enExample)
WO (1) WO2021129653A1 (enExample)
ZA (1) ZA202208051B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
KR20230024328A (ko) 2020-06-12 2023-02-20 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
IL301690A (en) * 2020-10-16 2023-05-01 Dana Farber Cancer Inst Inc Piperidinyl small molecule degraders of helios and methods of use
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
TW202317546A (zh) 2021-07-09 2023-05-01 美商普萊克斯姆公司 調節ikzf2之芳基化合物及醫藥組合物
WO2024002205A1 (en) * 2022-06-30 2024-01-04 Anhorn Medicines Co., Ltd. Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same
CN119948021A (zh) * 2022-07-15 2025-05-06 西藏海思科制药有限公司 一种含氮杂环衍生物及其组合物和药学上的应用
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245804B1 (en) 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
RU2689988C2 (ru) 2015-04-21 2019-05-30 Джи Ти Икс, ИНК. Селективные лиганды-разрушители андрогенных рецепторов (sard) и способы их применения
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
SI3526202T1 (sl) * 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
AU2017363257B2 (en) * 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
US10842878B2 (en) 2016-11-22 2020-11-24 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
CN110194762B (zh) 2018-02-27 2021-09-10 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途
CN112390852B (zh) 2019-08-14 2022-10-18 上海济煜医药科技有限公司 作为蛋白降解剂的化合物及其制备方法和应用
CN112457367B (zh) 2019-09-06 2022-08-23 上海济煜医药科技有限公司 作为蛋白降解剂的连环类化合物及其制备方法和应用
CN118085015A (zh) 2019-09-06 2024-05-28 江西济民可信集团有限公司 作为蛋白降解剂的并环类化合物及其制备方法和用途
CN112574278B (zh) 2019-09-29 2024-08-23 江西济民可信集团有限公司 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
CN113582974B (zh) 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
KR20230024328A (ko) 2020-06-12 2023-02-20 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도

Similar Documents

Publication Publication Date Title
JP2023531390A5 (enExample)
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
RU2006112428A (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2011509309A5 (enExample)
JP2022023958A5 (enExample)
JP2024518554A5 (enExample)
RU2009103810A (ru) Новые соединения
JP2018524390A5 (enExample)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2007507494A5 (enExample)
RU2018106453A (ru) Соединения
JP2016518437A5 (enExample)
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2023531517A5 (enExample)
JP2012522759A5 (enExample)
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2023522177A5 (enExample)
JP2022529371A5 (enExample)
RU2010116708A (ru) Бициклическое производное гамма-аминокислоты
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
CN110225781A (zh) 噻唑衍生物及其应用
JP2019529460A5 (enExample)
JP2022529309A5 (enExample)
JP2021521178A5 (enExample)
JP2023522725A5 (enExample)